SLC22A5 and gastrointestinal stromal tumor: In this line, in patients with gastrointestinal stromal tumors treated with imatinib, the time to progression period was significantly improved in carriers of the C allele of the SLC22A4 variant c.1507C>T (p.Leu503Phe, rs1050152), as well as in carriers of the minor alleles of the SLC22A5 variants c.-207C>G/A/T (rs2631367) and c.-2087G>C (rs2631372), both located at the promoter, suggesting that OCTN1 and OCTN2 activity or expression may predict the efficacy of imatinib chemotherapy[98].